Safety of vaginal oestrogens for genitourinary symptoms in women with breast cancer
Authors:
- 1 May 2024
- journal article
- research article
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 53 (5) , 305-310
Abstract
This article provides a summary of the data on the safety of vaginal oestrogens in women with breast cancer to help GPs advise their patients in this situation.Keywords
This publication has 24 references indexed in Scilit:
- Vaginal Estrogen Therapy Use and Survival in Females With Breast CancerJAMA Oncology, 2024
- Estrogen therapy after breast cancer diagnosis and breast cancer mortality riskBreast Cancer Research and Treatment, 2023
- Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic reviewThe Breast, 2022
- Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of MenopauseJournal of Obstetrics and Gynaecology Canada, 2020
- The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysisClinical Breast Cancer, 2019
- Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)Supportive Care in Cancer, 2017
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trialsBreast Cancer Research and Treatment, 2015
- Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control studyBreast Cancer Research and Treatment, 2012
- “First uterine pass effect” is observed when estradiol is placed in the upper but not lower third of the vaginaFertility and Sterility, 2004